Table 1 Characteristics of incident psoriasis patients at diagnosis, n = 10,832
Characteristics | Males (n = 5281) | Females (n = 5551) | All (n = 10,832) |
|---|---|---|---|
Age, years (mean, SD) | 48.5 (17.1)* | 49.4 (18.3) | 49.0 (17.8) |
Body mass index, kg/m2 (mean, SD) | 27.4 (5.3) | 27.6 (6.4) | 27.5 (5.9) |
Comorbidities at index, % | Â | Â | Â |
Hypertension | 24.1 | 24.6 | 24.3 |
Cardiovascular disease | 10.7 | 7.7 | 9.1 |
Chronic obstructive pulmonary disease | 7.0 | 7.2 | 7.1 |
Diabetes mellitus | 7.5 | 6.8 | 7.1 |
Heart failure | 1.2 | 0.8 | 1.0 |
Cancer | 4.3 | 6.3 | 5.3 |
Rheumatoid arthritis | 4.4 | 6.3 | 5.4 |
Psoriatic arthritis | 2.3 | 2.6 | 2.4 |
Eczema | 29.0 | 34.1 | 31.6 |
Other autoimmune diseases†| 5.5 | 11.4 | 8.5 |
Liver disease | 0.04 | 0.2 | 0.1 |
Dyslipidemia | 9.4 | 8.1 | 8.7 |
Number of comorbid conditions, % | Â | Â | Â |
0 | 43.7 | 37.4 | 40.5 |
1 | 31.9 | 33.0 | 32.5 |
2 or more | 24.4 | 29.6 | 27.1 |
Townsend deprivation quintile, % | Â | Â | Â |
1 | 23.9 | 22.6 | 23.3 |
2 | 20.7 | 20.4 | 20.6 |
3 | 21.0 | 21.2 | 21.1 |
4 | 16.9 | 17.6 | 17.3 |
5 | 13.0 | 13.4 | 13.2 |
Psoriasis-related therapies at index, % | Â | Â | Â |
Vitamin D3 analogues | 45.5* | 34.7 | 39.9 |
Retinoids | 0.04 | 0.07 | 0.06 |
Tar & tar combination products | 12.0 | 15.9 | 14.0 |
Anthracin & combination products | 0.6 | 0.5 | 0.6 |
Salicylic acid | 0.8 | 0.8 | 0.8 |
Corticosteroids | 34.9 | 43.6 | 39.4 |
Phototherapy | 0 | 0.04 | 0.02 |
Non-biologic systemic therapy | 0.6 | 0.8 | 0.7 |
Any psoriasis-related medication at index, % | 80.6 | 80.1 | 80.4 |